Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Apotex Manufacturing Violations Could Delay Launch Of Taxotere Generic

Executive Summary

FDA's warning letter to Apotex for continued manufacturing violations could delay the launch of the company's generic version of the cancer drug Taxotere (docetaxel)
Advertisement

Related Content

Apotex’s Generic Approvals Delayed By FDA Paperwork Snafu, Lawsuit Says
FDA Import Alert Lifted, Apotex Says; Will Lipitor ANDA Approvals Be Far Behind?
FDA Import Alert Lifted, Apotex Says; Will Lipitor ANDA Approvals Be Far Behind?
Alkermes To Put Its Long-Acting Stamp On Trusted Blockbusters, Starting With Abilify
Ranbaxy Transfers Atorvastatin, Tamsulosin Filings To U.S. Ohm Labs After FDA Crackdown

Topics

Advertisement
UsernamePublicRestriction

Register

PS052128

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel